Savara (SVRA) FCF Margin (2013 - 2020)

Savara (SVRA) reported FCF Margin of 1230500.0% for Q4 2020, down 46755.27% quarter-over-quarter from 2626.17% in Q3 2020.

Savara (SVRA) FCF Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has 5 years of FCF Margin data on file, last reported at 1230500.0% in Q4 2020.

FCF Margin for Q4 2020 came in at 1230500.0%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was 3896000.0% (changed N/A YoY), and the FY2020 annual result was 15518.68%, changed N/A from the prior year.
FCF Margin retreated to 1230500.0% in Q4 2020 per SVRA's latest filing, from 2626.17% in the prior quarter.
Over five years, FCF Margin peaked at 8161.7% in Q2 2017 and troughed at 1230500.0% in Q4 2020.
A 3-year average of 205828.93% and a median of 2857.23% in 2020 frame the typical range for FCF Margin.
On a YoY basis, FCF Margin climbed as much as 3631231 bps in 2016 and fell as far as 3631231 bps in 2016.
A 3-year view of FCF Margin shows it stood at 547.5% in 2016, then soared by 1591 bps to 8161.7% in 2017, then slumped by 15177 bps to 1230500.0% in 2020.
Business Quant data shows SVRA's FCF Margin at 1230500.0% in Q4 2020, 2626.17% in Q3 2020, and 8161.7% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-3.98%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	43.35%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Savara	1.33 Bn	1.33 Bn	-	-

Download Data